Abstract
Background Airflow limitation is the hallmark of obstructive pulmonary diseases, with the distal airways representing a major site of obstruction. Although numerous in vitro models of bronchi already exist, there is currently no culture system for obstructive diseases that reproduces the architecture and function of small airways. Here, we aimed to engineer a model of distal airways to overcome the limitations of current culture systems.
Methods We developed a so-called bronchioid model by encapsulating human bronchial adult stem cells derived from clinical samples in a tubular scaffold made of alginate gel.
Results This template drives the spontaneous self-organisation of epithelial cells into a tubular structure. Fine control of the level of contraction is required to establish a model of the bronchiole, which has a physiologically relevant shape and size. 3D imaging, gene expression and single-cell RNA-seq analysis of bronchioids made of bronchial epithelial cells revealed tubular organisation, epithelial junction formation and differentiation into ciliated and goblet cells. Ciliary beating is observed, at a decreased frequency in bronchioids made of cells from COPD patients. The bronchioid can be infected by rhinovirus. An air-liquid interface is introduced that modulates gene expression.
Conclusion Here, we provide a proof of concept of a perfusable bronchioid with proper mucociliary and contractile functions. The key advantages of our approach, such as the air‒liquid interface, lumen accessibility, recapitulation of pathological features and possible assessment of clinically relevant endpoints, will make our pulmonary organoid-like model a powerful tool for preclinical studies.
Footnotes
This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.
Conflict of Interest: A. Versi has nothing to disclose.
Conflict of interest: Regarding conflicts of interest, ID and PB have 2 patents (EP N°3050574 and EP N°20173595). ID, PH and MZ report grants from the “Fondation Bordeaux Université”. MZ reports personal fees from AstraZeneca, Boehringer Ingelheim, CSL Behring, Novartis, Chiesi, GlaxoSmithKline and nonfinancial support Lilly. PB reports grants and personal fees from Novartis; personal fees and nonfinancial support from Chiesi, Boehringer Ingelheim, AstraZeneca and Sanofi; and personal fees from Menarini and TEVA, outside the submitted work. All the other authors declare that they have no competing interests.
This is a PDF-only article. Please click on the PDF link above to read it.
- Received May 9, 2023.
- Accepted July 21, 2024.
- Copyright ©The authors 2024. For reproduction rights and permissions contact permissions{at}ersnet.org